Kura Oncology Inc (NASDAQ: KURA) kicked off on Monday, down -6.38% from the previous trading day, before settling in for the closing price of $7.05. Over the past 52 weeks, KURA has traded in a range of $6.79-$23.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 10.35%. With a float of $75.15 million, this company’s outstanding shares have now reached $78.23 million.
Let’s determine the extent of company efficiency that accounts for 192 employees. In terms of profitability, gross margin is 99.19%, operating margin of -316.87%, and the pretax margin is -319.15%.
Kura Oncology Inc (KURA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Kura Oncology Inc is 6.94%, while institutional ownership is 96.07%. The most recent insider transaction that took place on Mar 21 ’25, was worth 181,456. In this transaction Director of this company sold 22,682 shares at a rate of $8.00, taking the stock ownership to the 23,983 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Director proposed sale 30,000 for $7.85, making the entire transaction worth $235,500.
Kura Oncology Inc (KURA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.45% during the next five years compared to -6.05% drop over the previous five years of trading.
Kura Oncology Inc (NASDAQ: KURA) Trading Performance Indicators
Take a look at Kura Oncology Inc’s (KURA) current performance indicators. Last quarter, stock had a quick ratio of 9.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.89. Likewise, its price to free cash flow for the trailing twelve months is 3.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.02, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -1.85 in one year’s time.
Technical Analysis of Kura Oncology Inc (KURA)
Looking closely at Kura Oncology Inc (NASDAQ: KURA), its last 5-days average volume was 0.79 million, which is a drop from its year-to-date volume of 1.46 million. As of the previous 9 days, the stock’s Stochastic %D was 12.30%. Additionally, its Average True Range was 0.44.
During the past 100 days, Kura Oncology Inc’s (KURA) raw stochastic average was set at 1.24%, which indicates a significant decrease from 10.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.00% in the past 14 days, which was lower than the 87.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.79, while its 200-day Moving Average is $14.67. However, in the short run, Kura Oncology Inc’s stock first resistance to watch stands at $6.89. Second resistance stands at $7.18. The third major resistance level sits at $7.40. If the price goes on to break the first support level at $6.37, it is likely to go to the next support level at $6.15. Now, if the price goes above the second support level, the third support stands at $5.86.
Kura Oncology Inc (NASDAQ: KURA) Key Stats
The company with the Market Capitalisation of 532.98 million has total of 80,755K Shares Outstanding. Its annual sales at the moment are 53,880 K in contrast with the sum of -173,980 K annual income. Company’s last quarter sales were recorded 53,880 K and last quarter income was -19,220 K.
